Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation

Traumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, m...

Full description

Bibliographic Details
Main Authors: Shruti V. Kabadi, Alan I. Faden
Format: Article
Language:English
Published: MDPI AG 2014-01-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/15/1/1216
id doaj-a225b2c7a82248cc8e220a167e752f74
record_format Article
spelling doaj-a225b2c7a82248cc8e220a167e752f742020-11-24T21:50:01ZengMDPI AGInternational Journal of Molecular Sciences1422-00672014-01-011511216123610.3390/ijms15011216ijms15011216Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical TranslationShruti V. Kabadi0Alan I. Faden1Department of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research (STAR), National Study Center for Trauma and EMS, University of Maryland School of Medicine, Baltimore, MD 21201, USADepartment of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research (STAR), National Study Center for Trauma and EMS, University of Maryland School of Medicine, Baltimore, MD 21201, USATraumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, more than 30 clinical trials of neuroprotection in TBI patients have failed. In part, these failures likely reflect methodological differences between the clinical and animal studies, as well as inadequate pre-clinical evaluation and/or trial design problems. However, recent changes in experimental approach and advances in clinical trial methodology have raised the potential for successful clinical translation. Here we critically analyze the current limitations and translational opportunities for developing successful neuroprotective therapies for TBI.http://www.mdpi.com/1422-0067/15/1/1216experimental head injury clinical trial design translational challenges multipotential neuroprotective approachesprogrammed cell death caspase-dependent and AIF-mediated cell death microglial and astrocyte activation autophagy
collection DOAJ
language English
format Article
sources DOAJ
author Shruti V. Kabadi
Alan I. Faden
spellingShingle Shruti V. Kabadi
Alan I. Faden
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
International Journal of Molecular Sciences
experimental head injury
clinical trial design
translational challenges
multipotential neuroprotective approaches
programmed cell death
caspase-dependent and AIF-mediated cell death
microglial and astrocyte activation
autophagy
author_facet Shruti V. Kabadi
Alan I. Faden
author_sort Shruti V. Kabadi
title Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
title_short Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
title_full Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
title_fullStr Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
title_full_unstemmed Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
title_sort neuroprotective strategies for traumatic brain injury: improving clinical translation
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2014-01-01
description Traumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, more than 30 clinical trials of neuroprotection in TBI patients have failed. In part, these failures likely reflect methodological differences between the clinical and animal studies, as well as inadequate pre-clinical evaluation and/or trial design problems. However, recent changes in experimental approach and advances in clinical trial methodology have raised the potential for successful clinical translation. Here we critically analyze the current limitations and translational opportunities for developing successful neuroprotective therapies for TBI.
topic experimental head injury
clinical trial design
translational challenges
multipotential neuroprotective approaches
programmed cell death
caspase-dependent and AIF-mediated cell death
microglial and astrocyte activation
autophagy
url http://www.mdpi.com/1422-0067/15/1/1216
work_keys_str_mv AT shrutivkabadi neuroprotectivestrategiesfortraumaticbraininjuryimprovingclinicaltranslation
AT alanifaden neuroprotectivestrategiesfortraumaticbraininjuryimprovingclinicaltranslation
_version_ 1725885849441140736